Gibson Dunn Advises Korsana Biosciences on Merger with Cyclerion Therapeutics
Firm News | April 7, 2026
Gibson Dunn is advising Korsana Biosciences on its merger with Cyclerion Therapeutics, Inc. and concurrent $380 million financing.
The firm’s corporate team includes partners Ryan Murr and Branden Berns and associate Evan Shepherd.